All News
Metformin Effective in Osteoarthritis
d
MedPage Today
The diabetes drug metformin provided overweight/obese patients with osteoarthritis (OA) of the knee with significantly greater pain relief than did placebo in a small randomized trial, researchers said.
Read Article
2024 Management of Familial Mediterranean Fever Recommendations
A EULAR/PReS combined task force has developed recommendations for the management of Familial Mediterranean fever (FMF), the most common monogenic autoinflammatory disease worldwide. These evidence-based recommendations update the 2016 recommendations developed for rheumatologists and other HCPs who care for FMF patients.
Read Article
No Extra Cancer Recurrence Risk with Biologics in RA
d
MedPage Today
Rheumatoid arthritis (RA) patients in Denmark with a history of solid tumor cancers, now in remission, faced no greater likelihood of cancer relapse when they were treated with biologic agents, compared with conventional disease-modifying anti-rheumatic drugs (DMARDs).
Read Article
Osteoarthritis Initiative (OAI) longitudinal study analyzed 1075 #OA knees (1/pt) in 96 mo. MRI study to predict outcomes. Infrapatellar fat pad (IPFP volume & signal) predicted future knee replacement & long-term damage. IPFP correlated w/ cartil. volume & BM lesions; Not https://t.co/VrLfiSGWGA
Dr. John Cush RheumNow ( View Tweet)
Vitamin D for Prevention of Disease
JAMA has published a clinical guideline on the use of vitamin D to prevent disease in children and adults. Guideline committee experts, included adult and pediatric endocrinology, internal medicine, obstetrics/gynecology, nutrition, and https://t.co/zi3CpE0DVN
Dr. John Cush RheumNow ( View Tweet)
Simplistic overview of Lupus Nephritis - causes, risk factors, symptoms, diagnosis, and treatment of lupus nephritis. https://t.co/QkLXUQcSqo https://t.co/pGjCHmoelG
Dr. John Cush RheumNow ( View Tweet)
Unmet Needs in Still’s disease
In February 2023, an expert consensus panel of pediatric and adult rheumatologists met to address challenges in Still’s disease (SD), including systemic juvenile idiopathic arthritis (sJIA) and adult-onset SD (AOSD). They addressed four main https://t.co/h6FNkQyoKj
Dr. John Cush RheumNow ( View Tweet)
2025 BSR Guideline for Treatment of Axial Spondyloarthritis
The British Society of Rheumatology has published its 2025 Guidelines for the Treatment of Axial Spondyloarthritis (axSpA); addressing axial and extra-musculoskeletal manifestations including acute anterior uveitis, https://t.co/IRdxsZTFdC
Dr. John Cush RheumNow ( View Tweet)
“Always laugh when you can. It is cheap medicine."
– Lord Byron https://t.co/SWfnTPEJs0
Dr. John Cush RheumNow ( View Tweet)
Better Responses with Chronotherapy for Baricitinib
A nonrandomized, open-label, controlled trial has shown superior efficacy when baricitinib was given at night (instead of day); attesting to the benefits of chronotherapy - selective dosing meant to target the body's diurnal https://t.co/jSrPdoOpmo
Dr. John Cush RheumNow ( View Tweet)
Post-treatment Lyme Syndrome
Symptoms that persist long after Lyme disease is treated are not uncommon — a 2022 study found that 14% of patients who were diagnosed and treated early with antibiotic therapy would still develop Post Treatment Lyme Disease (PTLD). https://t.co/mmwGCnARY8
Dr. John Cush RheumNow ( View Tweet)
Senescent "Zombie" Cells and Low Back Pain
In a preclinical study led by McGill University researchers, two drugs targeting “zombie cells” have been shown to treat the underlying cause of chronic low back pain. The condition affects millions of people worldwide. https://t.co/UxHH3bMGkQ
Dr. John Cush RheumNow ( View Tweet)
Diabetes Prevention with Hydroxychloroquine in Sjogren’s
A Taiwanese insurance claims analysis looked at HCQ use in primary Sjögren syndrome (pSS) and showed that HCQ exposure significantly reduces the risk of new onset diabetes in pSS. Conversely, higher doses of https://t.co/GS07GVp5pC
Dr. John Cush RheumNow ( View Tweet)
🦋 This May, RheumNow brings you Lupus Unlocked – Keys to Mastery
Your one-stop hub for lupus education:
✅ Expert KOL content
✅ Weekly webinars & podcasts
✅ Engaging surveys + slides
Sponsored by Aurinia — empowering HCPs to advance care.
#Lupus #Rheumatology https://t.co/rf4GveV3eh
Dr. John Cush RheumNow ( View Tweet)
Metanalysis suggests MTX may be effective in knee OA. 6RCTs, 602 pts of MTX vs PBO, showed MTX significantly relieved pain (mean diff −0.44; P 0.0003) knee/hand OA; Functional improved for knee only, but no differences in quality-of-life outcome or adverse events https://t.co/lmBEnTLFHY
Dr. John Cush RheumNow ( View Tweet)
Incr. neutrophils in RA synovium correlates w/ higher Dz activity and poorer Rx responses. Study of 55 #RA pts, 1/3 (17) enriched for synovial PMNs - these correlated w/ DAS28--CRP, synovial inflammation, and CD3+/CD68+ cell counts https://t.co/zz59w8MMUU https://t.co/R7Ruyab0wj
Dr. John Cush RheumNow ( View Tweet)
Prevalence of ANCA Assoc Vasculitis (especially GPA) in Alaskan Natives (AN/AI) is high. GCA prevalence is lower than White populations, but higher than many others. AN/AI peoples w/ AAV & GCA may present at younger ages with more severe disease https://t.co/dhiu6sPGBk https://t.co/rNCo25HGcn
Dr. John Cush RheumNow ( View Tweet)
Pairwise Network Metanalysis suggests that JAKi use may NOT be assoc w/ Gastrointestinal perforation (GIP), as suggested by the PI. 23 RCTs, (20,023 pts) followed for 24 wks. Incidence of JAKi GIP=0.19%. compared to csDMARDs this was not signif increased (RR 1.02; CI: 0.41-2.56). https://t.co/lLD9Tj6a9F
Dr. John Cush RheumNow ( View Tweet)
Better Responses with Chronotherapy for Baricitinib
A nonrandomized, open-label, controlled trial has shown superior efficacy when baricitinib was given at night (instead of day); attesting to the benefits of chronotherapy - selective dosing meant to target the body's diurnal https://t.co/pEJIsJq0wE
Dr. John Cush RheumNow ( View Tweet)
84 RA pts on CZP+MTX w/sustained LDA (CDAI ≤10) ≥ 12 wks. 1/2 OL withdrawal of MTX & @ wk 36, LDA was maintained in 85% on CZP+MTX vs 84% on CZP alone (w latter group having signif less GI Sxs (2.4% vs. 15.8%, P = 0.034) https://t.co/jGlNlmkae4 https://t.co/6e0ySRrRD4
Dr. John Cush RheumNow ( View Tweet)